Boston Scientific Corporation vs Exxon Mobil Corporation — how do they compare? Boston Scientific Corporation trades at $42.62 (market cap $66.37B), while Exxon Mobil Corporation trades at $145.11 (market cap $601.39B). The key difference: Exxon Mobil Corporation is far larger — about 9.1× Boston Scientific Corporation's market cap, and Exxon Mobil Corporation pays a 2.84% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | XOM | |
|---|---|---|
Market Cap | $66.37B | $601.39B |
Sector | Health | Energy |
52-Week High | $108.14 | $171.52 |
52-Week Low | $42.63 | $105.83 |
Enterprise Value | $75.94B | $640.62B |
Dividend Yield | — | 2.84% |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
ExxonMobil (XOM) trades at $144.51, up 4.1% today, with a bullish technical outlook and strong earnings beats in recent quarters. The stock shows robust profitability with a net income margin of 7.76% and a solid balance sheet, though revenue and net income have declined from 2022 peaks. Recent news highlights Exxon's Permian Basin advantages and potential oil price spikes, supporting positive sentiment.
XOM offers value with a consensus price target of $169.30, implying 17% upside, but faces risks from volatile oil prices and declining profit margins. Institutional buy ratings at 40.74% reflect cautious optimism, while technical indicators suggest near-term resistance at $146. Investors should weigh the strong cash flow and dividend against energy market uncertainties.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →